Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-HTT02 in Adult Patients With Huntington's Disease
NCT06585449Phase 1Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Oct 2024
- Primary completion
- Jul 2028
- Modality
- Lipid-based Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in Huntington's disease (HD) comparing ALN-HTT02 with Placebo + ALN-HTT02 (2 arms). Primary endpoint: Adverse Events at 36 months. Started Oct 2024; status: recruiting.
02
Drugs
ALN-HTT02
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT06585449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06585449.